Passion, Plants, and Phase III: Devonian Health Group Is on a Mission to Disrupt Inflammation Therapy
While the industry might be dominated by synthetic compounds, billion-dollar VC funds, and long, uncertain development timelines, Devonian Health Group Inc. is proving there is another way. As a publicly traded company, under the leadership of its founder and CEO, Dr. André P. Boulet, Devonian has quietly advanced multi-target drug candidates and a cutting-edge cosmeceutical line, backed not by institutional investors but by a network of Canadian family offices made up of dentists, physicians, engineers, and entrepreneurs.
Boulet's journey to this unconventional success story reads like a masterclass in risk, reinvention, and scientific conviction. "I'm a venture capitalist in my heart," Boulet says. "But I'm also a scientist. When I saw the anti-inflammatory results of this botanical extract technology from a university agriculture project, I knew this had real potential. So, I followed my instinct and took the risk."
With a PhD in physiology-endocrinology, postdoctoral training in biochemistry and biophysics, and experience leading cardiovascular clinical research programs, Boulet's transition from academia to venture capital was swift. After climbing the pharmaceutical ladder and managing funds in Montreal, he exited his partnership and launched what would become Devonian Health Group in 2015.
At its core, Devonian is a clinical-stage pharmaceutical company focused on autoimmune and inflammatory conditions, with its lead drug candidate, Thykamine ™, poised to enter Phase III clinical trials for atopic dermatitis and soon pediatric eczema.
"Traditional pharma was built on the 'silver bullet,' one target, one mechanism," Boulet explains. "But now science is evolving. We're moving toward therapies that modulate multiple pathways. That's exactly what Thykamine does without shutting down important immune functions like TNF-alpha. That's why our efficacy is high, but side effects are minimal."
What sets Devonian apart isn't just its marquee drug but the platform behind it. The company's patented SUPREX™ technology allows for water-based extraction, purification, and stabilization of Active Botanical Ingredients (ABIs) from plants and algae. These complexes modulate inflammation at the genetic level across multiple diseases, offering a broad pipeline of possibilities.
To date, Thykamine™ has demonstrated strong results in its Phase II trial. Both gastrointestinal (ulcerative colitis) and dermatological (eczema) models have shown significant symptom relief and safety comparable to placebo.
Remarkably, all this has been achieved without traditional VC backing. Boulet credits this to his deep network of entrepreneurial allies and his belief in business-first partnerships. "We've raised funds to advance to Phase III, built an extraction and production facility, and kept the company debt-free," he says.
While the pharmaceutical arm garners headlines, Devonian's cosmeceutical division is equally ambitious. Operating under the Purgenesis™ brand, the company has developed a premium line of anti-aging creams containing its patented botanical ingredient R-Spinasome®, a photosynthetic cell extract with dynamic antioxidant properties.
What makes Purgenesis™ unusual in the beauty space is its clinical rigor. Devonian has conducted peer-reviewed, pharma-grade clinical trials on the entire product line, something virtually unheard of in the cosmeceutical industry. "We've scientifically proven a reduction in wrinkles," says Boulet. "Not just pretty pictures, but peer-reviewed, published data. We're the only ones doing cosmeceuticals the pharma way."
With day, night, and eye creams already developed and a professional-grade serum in the pipeline, Devonian is currently seeking commercial partners to bring Purgenesis™ to a global market hungry for results-backed skincare.
Perhaps the most unusual aspect of Devonian's success is how personal it all feels. There are no Silicon Valley investors or hedge fund suits behind the curtain, just a network of entrepreneurs who believe in the mission. "Working with family offices is stimulating," Boulet says. "You get input from pharmacists, dentists, and industrialists. We face challenges together, and we have fun doing it."
The company's headquarters in Québec includes a full-scale extraction and production facility, providing complete traceability from seed to pill. This vertical integration helps with both cutting costs, yes, but also ensuring product consistency.
For Boulet, the journey has been one of passion and perseverance. "In life, there's always a risk," he reflects. "But if you surround yourself with the right people and believe in what you're building, that risk becomes your fuel. That's what Devonian is about: science, instinct, and community."
As the company readies for Phase III trials in both pharmaceuticals and final-stage commercialization of its skincare line, Devonian Health Group stands as a testament to the power of conviction and the potential of plants to reshape the future of medicine.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
DW
2 hours ago
- DW
US, Canada trade talks to resume after digital tax scrapped – DW – 06/30/2025
After Canada abandoned a planned digital services tax on US tech firms, trade negotiations between Ottawa and Washington are set to resume. Trade talks between the United States and Canada are set to resume this week after the latter scrapped plans for a digital services tax (DST) on US tech firms. Originally announced in 2020, the DST had foreseen a 3% levy on revenue earned from Canadian digital services users and would have impacted US companies such as Amazon, Meta and Apple. US President Donald Trump had slammed the proposed tax as a "blatant attack" and called off trade talks on Friday, threatening retaliatory tariffs on Canadian goods. But the planned tax was rescinded just hours before coming into effect and trade negotiations between the two sides are set to continue with an agreement expected by July 21, according to a statement from the Canadian Foreign Ministry. "Canada's preference has always been a multilateral agreement related to digital services taxation," it read, adding that the withdrawal of the DST comes "in anticipation of a mutually beneficial comprehensive trade arrangement with the United States." To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video Previously, the Canadian government had justified the DST as a step to address a shortfall in taxation on revenues generated from Canadians. The European Union (EU) has implemented a similar measure and Trump had accused Ottawa of mimicking Brussels. Canada is the United States' second-largest trading partner after Mexico, and the largest purchaser of US exports. Canada bought $349.4 billion (€297.4bn) of US goods last year and exported $412.7 billion (€351.3bn) worth in the opposition direction, according to the US Census Bureau.
Int'l Business Times
5 hours ago
- Int'l Business Times
Canada Rescinds Tax On US Tech Firms In Hopes Of Trump Trade Deal
Canada will rescind taxes impacting US tech firms that had prompted President Donald Trump to retaliate by calling off trade talks, Ottawa said Sunday, adding that negotiations with Washington would resume. The digital services tax, enacted last year, would have seen US service providers such as Alphabet and Amazon on the hook for a multi-billion-dollar payment in Canada by Monday, analysts have said. Washington has previously requested dispute settlement talks over the tax -- but on Friday Trump, who has weaponized US financial power in the form of tariffs, said he was ending trade talks with Ottawa in retaliation for the levy. He also warned that Canada would learn its new tariff rate within the week. But on Sunday, Ottawa binned the tax, which had been forecast to bring in Can$5.9 billion (US$4.2 billion) over five years. Finance Minister Francois-Philippe Champagne "announced today that Canada would rescind the Digital Services Tax (DST) in anticipation of a mutually beneficial comprehensive trade arrangement with the United States," a government statement said. It added that Trump and Canadian Prime Minister Mark Carney "have agreed that parties will resume negotiations with a view towards agreeing on a deal by July 21, 2025." There was no immediate comment from the White House or Trump. US Treasury Secretary Scott Bessent told CNBC on Friday that Washington had hoped Carney's government would halt the tax "as a sign of goodwill." Canada has been spared some of the sweeping duties Trump has imposed on other countries, but it faces a separate tariff regime. Since returning to the White House in January, Trump has also imposed steep levies on imports of steel, aluminum and autos. Canada is the largest supplier of foreign steel and aluminum to the United States. Last week, Carney said Ottawa will adjust its 25 percent counter tariffs on US steel and aluminum -- in response to a doubling of US levies on the metals to 50 percent -- if a bilateral trade deal was not reached in 30 days. "We will continue to conduct these complex negotiations in the best interest of Canadians," Carney said Friday. He had previously said a good outcome in the talks would be to "stabilize the trading relationship with the United States" and "ready access to US markets for Canadian companies" while "not having our hands tied in terms of our dealings with the rest of the world." Carney and Trump met on the sidelines of the Group of Seven summit in Canada earlier this month. Leaders at the summit pushed Trump to back away from his punishing trade war. Dozens of countries face a July 9 deadline for steeper US duties to kick in -- rising from a current 10 percent. It remains to be seen if they will successfully reach agreements before the deadline. Bessent has said Washington could wrap up its agenda for trade deals by September, indicating more agreements could be concluded, although talks were likely to extend past July.
Int'l Business Times
5 days ago
- Int'l Business Times
The Financial Partners Founder On How Smart Business Leaders Are Building Tax-Free Wealth Using Other People's Money
Most people think of life insurance as a cost, a necessary protection policy filed away in a drawer. But what if it could be one of the most powerful tax-free wealth-building tools available? That's the question, Michael (Mike) Smith, Managing Partner and founder of The Financial Partners Group (TFP), believes more business owners and high earners should be asking. "Premium financing life insurance has long been the playbook of the ultra-wealthy," Smith explains. "But the game has changed. We're now helping executives, entrepreneurs, and even professional athletes use this strategy to create tax-free income and preserve wealth for generations. And no, it's not as risky as most people assume." Premium financing is a strategy where a client borrows money from a third-party lender to fund a life insurance policy, usually an indexed universal life (IUL) or similar cash-value vehicle. Instead of tying up capital in hefty annual premiums, the client retains control of their cash while the policy accumulates value over time. According to Smith, this approach flips the traditional insurance conversation on its head. "We're not talking about paying $100 a month to get a death benefit. We're talking about using institutional strategies, used by billionaires, banks, and major corporations, to create a tax-advantaged retirement income and long-term wealth preservation vehicle." In short, the client gets access to market upside without downside risk, IRS-compliant tax-free income through policy loans or withdrawals, and significant death benefit protection for their heirs. Smith further shares that there are minimal upfront out-of-pocket costs. And the biggest kicker is it's built on borrowed money, what he calls "one of the most efficient ways to use leverage in the financial world." Historically, premium financing was reserved for the ultra-wealthy. But Smith says today's savvy professionals, especially those under 55 with strong income, are increasingly using the same tools. "The strategy works particularly well for business owners, executives, professionals, and athletes," he says. "People who have the income and credit profile to qualify, but who don't want to lock up massive amounts of capital." Take one instance that Smith portrays: a couple in their mid-50s earning $550,000 a year, with $5 million projected in retirement savings, all taxable. They want to double their projected retirement income to $40,000 per month tax-free. The traditional route would have required $25,000 per month in new savings. Instead, using premium financing and TFP's Legacy Plan™, they are able to commit just $25,000 per year, using collateral and lender capital to generate the same (or better) outcome. "That's a 12x difference in capital outlay," Smith emphasizes. "Same goal, dramatically different journey." Despite its advantages, premium financing has long been misunderstood, even within the financial advisory world. "A lot of advisors think it's too aggressive, too risky," Smith says. "But that's because they've never been properly educated on how the strategy works, or how the risk is managed. Once I walk them through the actual structure, their response is usually: 'Oh, this isn't nearly as risky as I thought.' And they're right." Smith points to several built-in safeguards: adjustable interest rates, liquidity buffers, collateral management, and carrier guarantees. "Like any financial tool, it has to be designed right. But the risks are far more manageable than most people believe." He adds that even major privately held insurance conglomerates are now leaning into premium financing. "They wouldn't even look at this space a few years ago. Now I'm one of their intermediaries, and they're fully behind it. This goes to show that, even the most conservative financial institutions are recognizing premium financing is an important planning opportunity. And is not as risky as once thought," Smith affirms. One of the most compelling aspects of the strategy is its tax advantage. If properly structured, both withdrawals and loans from the policy's cash value can be taken out tax-free, thanks to longstanding IRS rules protecting life insurance's unique status. "These aren't loopholes," Smith explains. "They're built into the tax code. The industry has powerful lobbying support because the products serve legitimate protection and planning needs. You're putting the money to work inside an IRS-recognized structure." Because of regulations passed in 1987, policies must adhere to specific funding limits, he agrees, but those limits still leave ample room for meaningful wealth growth. With higher tax rates on the horizon and more scrutiny on qualified retirement plans, Smith argues that professionals need smarter ways to diversify and preserve wealth. He states, "You spend your whole life building your business, your career, your income. Then retirement hits, and suddenly, you're giving a huge chunk of it away in taxes. Premium financing changes that trajectory." While the strategy isn't for everyone, health, age, and income requirements apply, Smith believes more advisors should be educating their clients. "This is advanced planning. It's what the best of the best are doing. And it's time more people knew about it."
